AMYLYX PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.83 USD | 0.00% |
|
+4.27% | -87.57% |
| May. 14 | Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $3 From $4, Keeps Neutral Rating | MT |
| May. 09 | Transcript : Amylyx Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The stock, which is currently worth 2024 to 0.38 times its sales, is clearly overvalued in comparison with peers.
- The company has a low valuation given the cash flows generated by its activity.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -87.57% | 124M | - | ||
| -2.32% | 92.59B | A- | ||
| +3.68% | 41.43B | A- | ||
| -10.90% | 33.49B | B- | ||
| -19.56% | 14.62B | C | ||
| -9.06% | 12.77B | B- | ||
| -11.34% | 11.58B | D+ | ||
| -43.53% | 11.35B | B | ||
| +3.75% | 8.97B | B+ | ||
| -6.32% | 8.3B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- AMLX Stock
- Ratings Amylyx Pharmaceuticals, Inc.
